Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZN-C5 + abemaciclib
- Development stage
- Phase 1
- Lead developer
- Zentalis Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**ZN-C5 + abemaciclib** is an investigational combination therapy evaluated in advanced or metastatic estrogen receptor (ER) positive, HER2-negative breast cancer. ZN-C5 is an oral selective estrogen receptor degrader (SERD) that targets and degrades the estrogen receptor to inhibit breast cancer growth. Abemaciclib is an oral small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), interfering with cell cycle progression and tumor cell proliferation. The combination aims to enhance anti-tumor activity by simultaneously blocking estrogen receptor signaling (via ZN-C5) and halting cell cycle progression (via abemaciclib). ZN-C5 is being developed by Zentalis Pharmaceuticals, and abemaciclib (brand name Verzenio) is developed and manufactured by Eli Lilly. This combination is under clinical investigation, primarily in Phase 1b trials, for the treatment of ER+/HER2- advanced breast cancer[1][3].
02
Targets
CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)ESR1 (ERα)
Beyond the preview
Go deeper on ZN-C5 + abemaciclib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZN-C5 + abemaciclib.